-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Zacks Small Cap Weighs in on ABVC BioPharma, Inc.'s Q1 2023 Earnings (OTCMKTS:ABVC)
Zacks Small Cap Weighs in on ABVC BioPharma, Inc.'s Q1 2023 Earnings (OTCMKTS:ABVC)
ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 EPS estimates for ABVC BioPharma in a report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.
Get ABVC BioPharma alerts:Separately, Maxim Group downgraded shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a research note on Wednesday, November 16th.
ABVC BioPharma Stock Performance
Shares of ABVC stock opened at $0.78 on Thursday. The company's fifty day simple moving average is $0.75 and its 200-day simple moving average is $0.79. ABVC BioPharma has a 52 week low of $0.50 and a 52 week high of $3.13. The company has a market cap of $25.45 million, a PE ratio of -1.15 and a beta of 0.50.ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.03 million.
About ABVC BioPharma
(Get Rating)
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
See Also
- Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 EPS estimates for ABVC BioPharma in a report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.
ABVC 生物製藥公司（OTCMKTS：ABVC-獲得評級）-扎克斯小型股在 1 月 18 日星期三發布的一份報告中發布了其 2023 年第一季度 ABVC 生物製藥的估計。扎克斯小型股分析師馬林預計，該公司將在本季度發布每股收益（0.05 美元）。ABVC 生物製藥目前全年盈利的共識估計為每股 0.56 美元。扎克斯小型股還發布了 ABVC 生物製藥 2023 年第二季度盈利（0.06 美元），2023 年第三季盈利為每股盈利（0.05 美元）和 2023 年第四季盈利（0.04 美元）的估計值。
Separately, Maxim Group downgraded shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a research note on Wednesday, November 16th.
另外，美心集團於 11 月 16 日（星期三）的研究報告中，將 ABVC 生物製藥的股份從「買入」評級下調至「持有」評級。
ABVC BioPharma Stock Performance
ABVC 生物製藥股票表現
ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.03 million.
ABVC 生物製藥（OTCMKTS：ABVC-獲取評級）上次公佈其季度業績於 11 月 14 日（星期一）。該公司報告了本季度每股盈利（0.11 美元），頂部分析師的共識估計（0.20 美元）為 0.09 美元。該公司本季的營收為 0.04 萬美元，而分析師的預期為 0.3 萬美元。
About ABVC BioPharma
關於 ABVC 生物製藥
(Get Rating)
(取得評分)
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
ABVC BioHharma, Inc. 是一家臨床階段生物製藥公司，致力於開發藥物和醫療設備，以滿足美國未滿足的醫療需求。公司正在開發 ABV-1501，目前正在進行 I/II 期臨床試驗，一種三陰性乳腺癌的聯合療法；ABV-1504 已完成重大抑鬱症的 II 期臨床試驗；ABV-1505 已完成治療胰腺癌的 I 期臨床試驗；已完成治療骨髓增生障礙的 I 期臨床試驗；ABV-1703 已完成治療胰腺癌的 I 期臨床試驗；治療癌症患者抑鬱症的臨床試驗；及 ABV-1702 ABV-1601ABV-1701 用於治療視網膜脫落或玻璃體出血的治療。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 獲取有關 ABVC 生物製藥研究報告的免費副本
- 市場節拍週的回顧 — 1/16 — 1/20
- 老自治領是否顯示卡車正在擊中剎車？
- 諾德斯特龍將對減價的恐懼放入零售業
- 埃克森美孚股票：在買入點的醒目距離內
- 高股息收益的必和必拓認為中國推動 23 年增長
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 ABVC 生物製藥的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 ABVC 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧